These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 30144998

  • 41. Blood routine risk factors for coronary artery aneurysm in infants younger than 8 months with Kawasaki disease.
    Haiyan G, Jianming L, Suqian T, Dong Q, Shuang L, Jin Z.
    BMC Pediatr; 2022 Jan 07; 22(1):29. PubMed ID: 34996405
    [Abstract] [Full Text] [Related]

  • 42. Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance.
    Ogihara Y, Ogata S, Nomoto K, Ebato T, Sato K, Kokubo K, Kobayashi H, Ishii M.
    Pediatr Res; 2014 Sep 07; 76(3):287-93. PubMed ID: 24964229
    [Abstract] [Full Text] [Related]

  • 43. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
    Youn Y, Kim J, Hong YM, Sohn S.
    Pediatr Infect Dis J; 2016 Apr 07; 35(4):457-9. PubMed ID: 26673981
    [Abstract] [Full Text] [Related]

  • 44. Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment.
    Downie ML, Manlhiot C, Collins TH, Chahal N, Yeung RSM, McCrindle BW.
    Int J Cardiol; 2017 Jun 01; 236():157-161. PubMed ID: 28089146
    [Abstract] [Full Text] [Related]

  • 45. Time Course of Coronary Artery Aneurysms in Kawasaki Disease.
    Tsuda E, Hashimoto S.
    J Pediatr; 2021 Mar 01; 230():133-139.e2. PubMed ID: 33301786
    [Abstract] [Full Text] [Related]

  • 46. Assessment of coronary artery abnormalities and variability of Z-score calculation in the acute episode of Kawasaki disease-A retrospective study from China.
    Liu HH, Qiu Z, Fan GZ, Jiang Q, Li RX, Chen WX, Liu FF, Wu Y, Wang JJ, Wu YF, Luo HH, Zhang DD, Hu P.
    Eur J Clin Invest; 2021 Mar 01; 51(3):e13409. PubMed ID: 32916764
    [Abstract] [Full Text] [Related]

  • 47. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S.
    J Rheumatol; 2012 Apr 01; 39(4):864-7. PubMed ID: 22337241
    [Abstract] [Full Text] [Related]

  • 48. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S, KIDCARE Multicenter Study Group.
    Lancet Child Adolesc Health; 2021 Dec 01; 5(12):852-861. PubMed ID: 34715057
    [Abstract] [Full Text] [Related]

  • 49. Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.
    Sakai H, Iwashima S, Sano S, Akiyama N, Nagata E, Harazaki M, Fukuoka T.
    Clin Drug Investig; 2021 Jan 01; 41(1):77-88. PubMed ID: 33341911
    [Abstract] [Full Text] [Related]

  • 50. A 5-year-old boy with only fever and giant coronary aneurysms: the enigma of Kawasaki disease?
    Vignesh P, Bhattad S, Singhal M, Singh S.
    Rheumatol Int; 2016 Aug 01; 36(8):1191-3. PubMed ID: 27154559
    [Abstract] [Full Text] [Related]

  • 51. Fifteen-minute consultation: Kawasaki disease: how to distinguish from other febrile illnesses: tricks and tips.
    Kelly A, Sales K, Fenton-Jones M, Tulloh R.
    Arch Dis Child Educ Pract Ed; 2020 Jun 01; 105(3):152-156. PubMed ID: 31900257
    [Abstract] [Full Text] [Related]

  • 52. Risk Factors of Coronary Artery Abnormalities and Resistance to Intravenous Immunoglobulin Plus Corticosteroid Therapy in Severe Kawasaki Disease: An Analysis of Post RAISE.
    Miyata K, Miura M, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H.
    Circ Cardiovasc Qual Outcomes; 2021 Feb 01; 14(2):e007191. PubMed ID: 33541111
    [Abstract] [Full Text] [Related]

  • 53. Clinical Presentation and Outcomes of Kawasaki Disease in Children from Latin America: A Multicenter Observational Study from the REKAMLATINA Network.
    Narayan HK, Lizcano A, Lam-Hine T, Ulloa-Gutierrez R, Bainto EV, Garrido-García LM, Estripeaut D, Del Aguila O, Gómez V, Faugier-Fuentes E, Miño-León G, Beltrán S, Cofré F, Chacon-Cruz E, Saltigeral-Simental P, Martínez-Medina L, Dueñas L, Luciani K, Rodríguez-Quiroz FJ, Camacho Moreno G, Viviani T, Alvarez-Olmos MI, Marques HHS, López-Medina E, Pirez MC, Tremoulet AH, Kawasaki Disease REKAMLATINA Network Study Group.
    J Pediatr; 2023 Dec 01; 263():113346. PubMed ID: 36775190
    [Abstract] [Full Text] [Related]

  • 54. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
    Kobayashi T, Kobayashi T, Morikawa A, Ikeda K, Seki M, Shimoyama S, Ishii Y, Suzuki T, Nakajima K, Sakamoto N, Arakawa H.
    J Pediatr; 2013 Aug 01; 163(2):521-6. PubMed ID: 23485027
    [Abstract] [Full Text] [Related]

  • 55. Giant aneurysms: A gender-specific complication of Kawasaki disease?
    Dietz SM, Kuipers IM, Tacke CEA, Koole JCD, Hutten BA, Kuijpers TW.
    J Cardiol; 2017 Oct 01; 70(4):359-365. PubMed ID: 28325522
    [Abstract] [Full Text] [Related]

  • 56. Infliximab as a novel therapy for refractory Kawasaki disease.
    Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS.
    J Rheumatol; 2004 Apr 01; 31(4):808-10. PubMed ID: 15088313
    [Abstract] [Full Text] [Related]

  • 57. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease.
    Koné-Paut I, Tellier S, Belot A, Brochard K, Guitton C, Marie I, Meinzer U, Cherqaoui B, Galeotti C, Boukhedouni N, Agostini H, Arditi M, Lambert V, Piedvache C.
    Arthritis Rheumatol; 2021 Jan 01; 73(1):151-161. PubMed ID: 32779863
    [Abstract] [Full Text] [Related]

  • 58. Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange.
    Fujimaru T, Ito S, Masuda H, Oana S, Kamei K, Ishiguro A, Kato H, Abe J.
    Cytokine; 2014 Dec 01; 70(2):156-60. PubMed ID: 25082649
    [Abstract] [Full Text] [Related]

  • 59. The effects of early intravenous immunoglobulin therapy for Kawasaki disease: The 22nd nationwide survey in Japan.
    Kuwabara M, Yashiro M, Ae R, Yanagawa H, Nakamura Y.
    Int J Cardiol; 2018 Oct 15; 269():334-338. PubMed ID: 30049499
    [Abstract] [Full Text] [Related]

  • 60. Status of treatment and outcome in Kawasaki disease in the Kinki area of Japan.
    Tsuchihashi T, Kakimoto N, Kitano N, Suenaga T, Ikeda K, Izui M, Kobayashi N, Yoshimura K, Nakamura Y, Suzuki H, steering committee of the Society of Kinki Area Kawasaki Disease Research.
    Pediatr Int; 2022 Jan 15; 64(1):e15391. PubMed ID: 36256501
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.